同时静脉给药后舒巴坦和氨苄西林的比较药代动力学及组织穿透性
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.
作者信息
Brown R M, Wise R, Andrews J M, Hancox J
出版信息
Antimicrob Agents Chemother. 1982 Apr;21(4):565-7. doi: 10.1128/AAC.21.4.565.
Abstract
A combination of 500 mg each of sulbactam and ampicillin was administered intravenously into six healthy male volunteers, and subsequent serum and blister fluid levels were measured. Both dogs had similar serum half-lives of about 1 h. The concentrations of sulbactam in serum and blister fluid were about 1.5 times those of ampicillin, and appeared to be pharmacokinetically well matched when administered in equal doses.
摘要
将舒巴坦和氨苄西林各500毫克的组合静脉注射给6名健康男性志愿者，随后测量血清和水疱液水平。两只狗的血清半衰期相似，约为1小时。血清和水疱液中舒巴坦的浓度约为氨苄西林的1.5倍，以等剂量给药时，在药代动力学上似乎匹配良好。
相似文献
1
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.同时静脉给药后舒巴坦和氨苄西林的比较药代动力学及组织穿透性
Antimicrob Agents Chemother. 1982 Apr;21(4):565-7. doi: 10.1128/AAC.21.4.565.
2
Penetration of sulbactam-ampicillin and clavulanic acid-amoxicillin into the pelvic peritoneum.舒巴坦-氨苄西林和克拉维酸-阿莫西林在盆腔腹膜中的渗透情况。
Antimicrob Agents Chemother. 1985 Jul;28(1):165-6. doi: 10.1128/AAC.28.1.165.
3
Pharmacokinetics of sulbactam/ampicillin in humans: a review.舒巴坦/氨苄西林在人体内的药代动力学：综述
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S503-11. doi: 10.1093/clinids/8.supplement_5.503.
4
The parenteral kinetics of ampicillin/sulbactam in man.氨苄西林/舒巴坦在人体中的肠胃外动力学。
Int J Clin Pharmacol Res. 1985;5(2):79-86.
5
Biliary pharmacokinetics of sulbactam plus ampicillin in humans.舒巴坦加氨苄西林在人体内的胆汁药代动力学。
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S589-92. doi: 10.1093/clinids/8.supplement_5.s589.
6
Penetration of sulbactam and ampicillin into peritoneal fluid.舒巴坦和氨苄西林在腹膜液中的穿透情况。
Antimicrob Agents Chemother. 1983 Aug;24(2):290-2. doi: 10.1128/AAC.24.2.290.
7
Pharmacokinetics of sultamicillin in mice, rats, and dogs.舒他西林在小鼠、大鼠和犬体内的药代动力学。
Antimicrob Agents Chemother. 1984 May;25(5):599-602. doi: 10.1128/AAC.25.5.599.
8
Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid.口服舒他西林并合用丙磺舒后舒巴坦和氨苄西林的药代动力学
Eur J Clin Microbiol. 1983 Aug;2(4):340-4. doi: 10.1007/BF02019464.
9
Concentration of sulbactam and ampicillin in serum and the myometrium.舒巴坦和氨苄西林在血清及子宫肌层中的浓度。
Drugs. 1986;31 Suppl 2:26-8. doi: 10.2165/00003495-198600312-00007.
10
Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.新生儿动脉内或静脉输注联合使用舒巴坦和氨苄西林的药代动力学研究。
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S518-22. doi: 10.1093/clinids/8.supplement_5.s518.
引用本文的文献
1
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.耐碳青霉烯鲍曼不动杆菌感染的治疗方法
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
2
Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.生物标志物预测脓毒症中抗菌药物的组织药代动力学：综述。
Clin Pharmacokinet. 2022 May;61(5):593-617. doi: 10.1007/s40262-021-01102-1. Epub 2022 Feb 25.
3
Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.用于外科手术预防的β-内酰胺类给药方案的药效学模型：基于模型的标准给药方案评估
Int J Clin Pharm. 2018 Oct;40(5):1059-1071. doi: 10.1007/s11096-018-0720-y. Epub 2018 Aug 16.
4
Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.开颅术后接受头孢哌酮/舒巴坦治疗患者的血清和脑脊液中的药物浓度。
BMC Anesthesiol. 2015 Mar 13;15:33. doi: 10.1186/s12871-015-0012-1. eCollection 2015.
5
Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.在接受结直肠手术的患者组织中，比较静脉推注或静脉推注加持续输注舒巴坦-氨苄西林的浓度。
Antimicrob Agents Chemother. 1998 May;42(5):1093-7. doi: 10.1128/AAC.42.5.1093.
6
Comparison of ampicillin-sulbactam regimens simulating 1.5- and 3.0-gram doses to humans in treatment of Escherichia coli bacteremia in mice.在小鼠大肠杆菌菌血症治疗中，模拟1.5克和3.0克剂量的氨苄西林-舒巴坦方案对人类的比较。
Antimicrob Agents Chemother. 1995 Apr;39(4):930-6. doi: 10.1128/AAC.39.4.930.
7
Pharmacokinetics of sultamicillin in mice, rats, and dogs.舒他西林在小鼠、大鼠和犬体内的药代动力学。
Antimicrob Agents Chemother. 1984 May;25(5):599-602. doi: 10.1128/AAC.25.5.599.
8
Penetration of sulbactam and ampicillin into peritoneal fluid.舒巴坦和氨苄西林在腹膜液中的穿透情况。
Antimicrob Agents Chemother. 1983 Aug;24(2):290-2. doi: 10.1128/AAC.24.2.290.
9
Pharmacokinetics of sulbactam in humans.舒巴坦在人体内的药代动力学。
Antimicrob Agents Chemother. 1983 May;23(5):692-9. doi: 10.1128/AAC.23.5.692.
10
Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis.舒巴坦和氨苄西林在患脑膜炎婴幼儿脑脊液中的穿透情况。
Antimicrob Agents Chemother. 1987 Nov;31(11):1703-5. doi: 10.1128/AAC.31.11.1703.
本文引用的文献
1
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.蛋白质结合对六种β-内酰胺类抗生素组织液水平的影响。
J Infect Dis. 1980 Jul;142(1):77-82. doi: 10.1093/infdis/142.1.77.
2
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.克拉维酸与CP-45,899：二者与青霉素联合应用的体外活性比较
J Antimicrob Chemother. 1980 Mar;6(2):197-206. doi: 10.1093/jac/6.2.197.
3
Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects.氨苄西林和海他西林在正常受试者和无肾受试者中的药代动力学。
Clin Pharmacol Ther. 1973 Jan-Feb;14(1):90-9. doi: 10.1002/cpt197314190.
4
Drug therapy. Clinical Pharmacokinetics (first of two parts).药物治疗。临床药代动力学（两部分中的第一部分）。
N Engl J Med. 1975 Oct 2;293(14):702-5. doi: 10.1056/NEJM197510022931406.
5
CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.CP-45899，一种可扩展β-内酰胺类抗菌谱的β-内酰胺酶抑制剂：初步细菌学特征
Antimicrob Agents Chemother. 1978 Sep;14(3):414-9. doi: 10.1128/AAC.14.3.414.
Zotero 插件